TL;DR
Findings support the Hydrazide–hydrazone derivatives' potential as EGFR kinase inhibitors, with M3 emerging as a particularly promising lead compound.
The findings from molecular docking, 500-ns molecular dynamics simulations, MM-GBSA calculations, and alanine scanning analyses collectively corroborate a stable binding mode of BTB11556 within the MPO active site, support further investigation of BTB11556 as a candidate compound associated with MPO-targeted therapeuti...
Overall, this study identifies selected 4-oxoquinazoline hydroxamic acid derivatives as preliminary computational leads for further experimental validation as potential HDAC8-targeting compounds.
Combined computational and preliminary cell-based findings support compound 4i as a promising lead for further investigation of EGFR-targeted anticancer activity and biochemical EGFR kinase inhibition and target-engagement studies are required to determine the mechanism of action.
This research developed a promising lead molecule (HIT1) as a therapeutic approach for ER-positive breast cancer through pharmacophore model-based drug design of thiazine derivative targeting ERα via pharmacophore model-based drug design.
This study highlights the usefulness of computational approaches in the discovery of novel isatin-based multi-target lead candidates for cancer therapy and suggests that compound 4 represents a promising lead for further investigation.
Light is shed on the structural prerequisites for anticancer action, which may aid in the rational development of more effective benzimidazole-based medicinal medicines, and emphasizing the significance of descriptors such as molar refractivity, partition coefficient, and related factors.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
